REAL-WORLD EFFICACY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-EXPERIENCED PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY

被引：1
|
作者：
Spengler, U. [1 ]
Schober, A. [2 ]
John, C. [3 ]
Bruch, H. R. [4 ]
Heyne, R. [3 ,5 ]
Antoni, C. [6 ]
Herrmann, A. [7 ]
Schott, E. [8 ]
Steffens, H.
Hoerster, H. -G. [9 ]
Hueppe, D. [10 ]
Alshuth, U. [11 ]
Mauss, S. [12 ]
Buggisch, P. [13 ]
机构：
[1] Univ Hosp Bonn, Dept Internal Med 1, Bonn, Germany
[2] Ctr Gastroenterol, Gottingen, Germany
[3] Ctr Gastroenterol, Berlin, Germany
[4] Ctr Gastroenterol, Bonn, Germany
[5] Ctr Liver, Berlin, Germany
[6] Univ Med Mannheim, Med Univ Klin 2, Mannheim, Germany
[7] Univ Basel Hosp, Dept Internal Med 2, Jena, Germany
[8] Campus Virchow Klinikum, Charite, Dept Gastroenterol, Berlin, Germany
[9] Ctr Gastroenterol, Monchengladbach, Germany
[10] Ctr Gastroenterol, Herne, Germany
[11] Roche Pharma AG, Virol, Grenzach Wyhlen, Germany
[12] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany
[13] Ifi Inst Interdisciplinary Med, Hamburg, Germany
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60910-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
908
引用
收藏
页码：S374 / S374
页数：1
相关论文
共 50 条
  • [1] REAL-WORLD EFFICACY AND SAFETY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
    Moog, G.
    Schober, A.
    Antoni, C.
    Bruch, H. R.
    Herrmann, A.
    John, C.
    Steffens, H.
    Leuschner, M.
    Spengler, U.
    Moeller, B.
    Isernhagen, K.
    Hueppe, D.
    Alshuth, U.
    Mauss, S.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S359 - S360
  • [2] REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
    Mauss, S.
    Boeker, K. H. W.
    Eisenbach, C.
    Moeller, B.
    Moog, G.
    Lutz, T.
    Naumann, U.
    Christensen, S.
    Jung, M. -C.
    Teuber, G.
    Doss, M. Frank
    Schuchmann, M.
    Schott, E.
    Alshuth, U.
    Hueppe, D.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S357 - S358
  • [3] Real-world efficacy and safety of 28 week-therapy containing boceprevir, peginterferon alfa-2a and ribavirin in treatment-naive patients: first SVR data of German non-interventional PAN Study
    Buggisch, Peter
    Schober, Andreas
    Bruch, Harald-Robert
    Antoni, Christoph
    Loehr, Hanns-Friedrich F.
    Herrmann, Andreas
    Steffens, Hermann
    Moog, Gero
    Haessner, Joachim
    Hoerster, Hans-Georg
    John, Christine
    Schlueter, Hans-Joachim
    Link, Ralph
    Heyne, Renate
    Spengler, Ulrich
    Alshuth, Ulrich
    Boeker, Klaus H.
    [J]. HEPATOLOGY, 2013, 58 : 1159A - 1159A
  • [4] Efficacy and safety of eRVR patients treated with telaprevir, peginterferon alfa-2A and ribavirin: SVR Data from the German non-interventional PAN Study
    Christensen, Stefan
    Boeker, Klaus H.
    Eisenbach, Christoph
    Schuchmann, Marcus
    Lutz, Thomas
    Heyne, Renate
    Moog, Gero
    Mauss, Stefan
    Jung, Maria-Christina
    Teuber, Gerlinde
    Emke, Franz
    Naumann, Uwe
    Doss, Margareta Frank
    von Lucadou, Armand
    Alshuth, Ulrich
    Hueppe, Dietrich
    [J]. HEPATOLOGY, 2013, 58 : 1127A - 1127A
  • [5] BASELINE CHARACTERISTICS AND TREATMENT EFFICACY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2a AND RIBAVIRIN IN 253 HCV GENOTYPE 1 NONRESPONDER PATIENTS IN A REAL-WORLD SETTING
    Hofmann, W. P.
    Mauss, S.
    Baumgarten, A.
    Boeker, K. H. W.
    Link, R.
    Naumann, U.
    Geyer, P. R.
    Schuchmann, M.
    Stoehr, A.
    Loehr, H.
    Schober, A.
    Moog, G.
    Holm, S.
    Heyne, R.
    Eisenbach, C.
    Lutz, T.
    Alshuth, U.
    Hueppe, D.
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S466 - S466
  • [6] SUSTAINED VIROLOGICAL RESPONSE (SVR) IN HCV TREATMENT-EXPERIENCED PATIENTS AFTER TRIPLE THERAPY WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING
    Boeker, K. H. W.
    Link, R.
    Baumgarten, A.
    Stoehr, A.
    Heyne, R.
    Roessle, M.
    Schott, E.
    Ullrich, R.
    Erren, P.
    Herold, C.
    Schmidt, W.
    Simon, K. -G.
    Geissler, M.
    Schiffelholz, W.
    Alshuth, U.
    Hueppe, D.
    Mauss, S.
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S462 - S463
  • [7] PEGINTERFERON ALFA-2A PLUS RIBAVIRIN COMBINATION TREATMENT IN CHRONIC HEPATITIS C POSTRENAL TRANSPLANT PATIENTS: AN INTERIM ANALYSIS
    Sanai, Faisal M.
    Mousa, Dujanah H.
    Aleid, Hassan
    AlShoail, Ghada
    AlMdani, Abdullah S.
    Al-Ashgar, Hamad I.
    Almeshari, Khalid A.
    Bzeizi, Khalid I.
    [J]. HEPATOLOGY, 2010, 52 (04) : 789A - 789A
  • [8] Beneficial effect of treatment individualization for patients with chronic hepatitis C receiving peginterferon alfa-2a and ribavirin in a large non-interventional cohort study
    Hofmann, Wolf P.
    Mauss, Stefan
    Zehnter, Elmar
    Hueppe, Dietrich
    Pfeiffer-Vornkahl, Heike
    Alshuth, Ulrich
    Schott, Eckart
    [J]. HEPATOLOGY, 2014, 60 : 703A - 703A
  • [9] TELAPREVIR COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN HCV/HIV COINFECTED PATIENTS: 24-WEEK TREATMENT INTERIM ANALYSIS
    Sherman, Kenneth E.
    Rockstroh, Juergen K.
    Dieterich, Douglas T.
    Soriano, Vincent
    Girard, Pierre-Marie
    McCallister, Scott
    Adda, Nathalie
    Adiwijaya, Bambang S.
    Mahnke, Lisa
    Sulkowski, Mark S.
    [J]. HEPATOLOGY, 2011, 54 : 1431A - 1431A
  • [10] Interim analysis of the safety and efficacy of peginterferon alfa-2a plus ribavirin in chronic hepatitis C patients unable to tolerate or nonresponsive to treatment with peginterferon alfa-2b plus ribavirin
    Rustgi, VK
    Esposito, S
    Freilich, B
    Lopez-Talavera, JC
    Lentz, E
    Shiffman, ML
    [J]. HEPATOLOGY, 2005, 42 (04) : 692A - 692A
12345